These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26635138)

  • 21. [Editorial].
    Özdemir M
    Turk Kardiyol Dern Ars; 2017 Sep; 45(Suppl 4):III. PubMed ID: 28947722
    [No Abstract]   [Full Text] [Related]  

  • 22. Optimal dosing of rivaroxaban is undefined.
    Moore TJ
    BMJ; 2016 Oct; 355():i5549. PubMed ID: 27756735
    [No Abstract]   [Full Text] [Related]  

  • 23. The efficacy of rivaroxaban in patients with atrial fibrillation.
    Carag MR; Arora RR
    Am J Ther; 2014; 21(5):412-8. PubMed ID: 22487774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
    Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
    Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Acute tubulo-interstitial nephritis due to RIVAROXABAN (XARELTO)].
    Dantec A; Virot JS; Filancia A; Angonin R; Nefti H
    Presse Med; 2017 May; 46(5):541-542. PubMed ID: 28483286
    [No Abstract]   [Full Text] [Related]  

  • 26. [The X-VeRT study].
    Colonna P; Troccoli R; Botto GL
    G Ital Cardiol (Rome); 2015 Jun; 16(6):325-8; discussion 328-30. PubMed ID: 26156692
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical significance of non-vitamin K antagonist oral anticoagulants in the management of atrial fibrillation.
    Santarpia G; Curcio A; Sibilio G; Indolfi C
    Circ J; 2015; 79(5):914-23. PubMed ID: 25833178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
    Washam JB; Stevens SR; Lokhnygina Y; Halperin JL; Breithardt G; Singer DE; Mahaffey KW; Hankey GJ; Berkowitz SD; Nessel CC; Fox KA; Califf RM; Piccini JP; Patel MR;
    Lancet; 2015 Jun; 385(9985):2363-70. PubMed ID: 25749644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].
    Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H
    Therapie; 2015; 70(6):485-92. PubMed ID: 26223162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct thrombin inhibitors: stroke prevention in atrial fibrillation and potential anti-inflammatory properties.
    Palagummi P; Saltzman H; Ezekowitz M
    Am Heart J; 2005 Jan; 149(1 Suppl):S32-5. PubMed ID: 15644791
    [No Abstract]   [Full Text] [Related]  

  • 31. The international normalized ratio range of 2.0 to 3.0 remains appropriate for atrial fibrillation.
    Singer DE; Fang MC; Go AS
    Arch Intern Med; 2009 Nov; 169(21):2032; author reply 2033. PubMed ID: 19933969
    [No Abstract]   [Full Text] [Related]  

  • 32. Stroke prevention in patients with atrial fibrillation: focus on new oral anticoagulants.
    Toth PP
    Postgrad Med; 2013 May; 125(3):155-61. PubMed ID: 23748516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apixaban: a new direct oral anticoagulant for stroke prevention in atrial fibrillation.
    Hohnloser SH
    Eur Heart J; 2014 Jul; 35(28):1828-9. PubMed ID: 25184177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-finding study of rivaroxaban in hemodialysis patients.
    De Vriese AS; Caluwé R; Bailleul E; De Bacquer D; Borrey D; Van Vlem B; Vandecasteele SJ; Emmerechts J
    Am J Kidney Dis; 2015 Jul; 66(1):91-8. PubMed ID: 25804678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. False-positive lupus anticoagulant in patients receiving rivaroxaban: 24 h since the last dose are needed to exclude antiphospholipid syndrome.
    Góralczyk T; Iwaniec T; Wypasek E; Undas A
    Blood Coagul Fibrinolysis; 2015 Jun; 26(4):473-5. PubMed ID: 25402189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rivaroxaban Used for Treatment of a Left Ventricular Thrombus in a Patient With Nonischemic Cardiomyopathy.
    Abubakar H; Yassin AS; Shokr M
    Am J Ther; 2018; 25(6):e706-e709. PubMed ID: 29324466
    [No Abstract]   [Full Text] [Related]  

  • 37. Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban.
    Königsbrügge O; Quehenberger P; Belik S; Weigel G; Seger C; Griesmacher A; Pabinger I; Ay C
    Ann Hematol; 2015 Sep; 94(9):1463-71. PubMed ID: 26025632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.
    Ezekowitz MD; Cappato R; Klein AL; Camm AJ; Ma CS; Le Heuzey JY; Talajic M; Scanavacca MI; Vardas PE; Kirchhof P; Hohnloser SH; Hemmrich M; Lanius V; Meng IL; Wildgoose P; van Eickels M
    Am Heart J; 2014 May; 167(5):646-52. PubMed ID: 24766973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. {blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.
    Drug Ther Bull; 2014 Jan; 52(1):6-9. PubMed ID: 24401533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study.
    Buller HR; Halperin J; Hankey GJ; Pillion G; Prins MH; Raskob GE
    J Thromb Haemost; 2014 Jun; 12(6):824-30. PubMed ID: 24597472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.